Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Asset Writedowns and Impairment (2016 - 2025)

IGC Pharma (IGC) has disclosed Asset Writedowns and Impairment for 8 consecutive years, with $152000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 104.66% to $152000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was -$3.1 million, a 4.66% increase, with the full-year FY2025 number at $152000.0, up 63.44% from a year prior.
  • Asset Writedowns and Impairment was $152000.0 for Q1 2025 at IGC Pharma, up from -$3.3 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $796000.0 in Q1 2022 to a low of -$3.3 million in Q1 2024.
  • A 4-year average of -$422200.0 and a median of $152000.0 in 2025 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 371.01% in 2022, then surged 104.66% in 2025.
  • IGC Pharma's Asset Writedowns and Impairment stood at $37000.0 in 2021, then surged by 2051.35% to $796000.0 in 2022, then crashed by 510.18% to -$3.3 million in 2024, then soared by 104.66% to $152000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Asset Writedowns and Impairment are $152000.0 (Q1 2025), -$3.3 million (Q1 2024), and $796000.0 (Q1 2022).